

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

September 23, 2026

To The Manager, Listing Department National Stock Exchange of India Limited Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
--	--

Sub.: Outcome of Board Meeting held today i.e. Wednesday, September 23, 2026 - Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) as amended from time to time.

Dear Sir/ Ma’am,

With reference to the intimation of Board meeting submitted on September 19, 2026, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Wednesday, September 23, 2026, has inter-alia considered and approved:

1. Issuance of Bonus shares:

Issuance of Bonus shares in the proportion of 1:1 i.e. 1 (One) Bonus equity share of Rs. 1/- each for every 1 (One) fully paid-up equity share of Rs. 1/- each held by the Shareholders of the Company as on the Record Date as may be decided by Board, by capitalization of the share premium account, subject to approval of the Shareholders of the Company.

Details pertaining to SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30, 2026 are enclosed as **Annexure-A**.

2. Increase in the Authorised Share Capital of the Company and consequent amendment to Clause V regarding Authorised Share Capital of Memorandum of Association of the Company:

Increase in the Authorised Share Capital of the Company **from** Rs. 11,00,00,000/- (Rupees Eleven Crores only), divided into 11,00,00,000 (Eleven Crores) Equity Shares of Rs. 1/- (Rupees One only) each, **to** Rs. 22,00,00,000/- (Rupees Twenty-two crores only), divided into 22,00,00,000 (Twenty-two crores) Equity Shares of Rs. 1/- (Rupees One only) each, by creation of an additional 11,00,00,000 (Eleven Crores) Equity Shares of Rs. 1/- (Rupees One only) each, ranking pari passu in all respects with the existing Equity Shares of the Company and consequential amendment to Capital Clause of the Memorandum of Association of the Company, subject to approval of the Shareholders.

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

Details pertaining to SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30, 2026 are mentioned below:

Brief details of amendment to the Memorandum of Association:

Alteration in Clause V of Memorandum of Association which shall be read as under:

The Authorised Share Capital of the Company shall be Rs. 22,00,00,000/- (Rupees Twenty-two crores only), divided into 22,00,00,000 (Twenty-two crores) Equity Shares of Rs. 1/- (Rupees One only) each.

The Board Meeting commenced at 03:30 P.M. and concluded at 04:05 P.M.

This is for your information and records.

For Concord Biotech Limited

Paritosh Trivedi
Company Secretary & Compliance Officer
ACS 63623

Encl : As above

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

Annexure-A

Issuance of Bonus Shares

Sr. No.	Particulars	Disclosures
a)	Type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Equity shares of Rs. 1/- each
b)	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Bonus Issue
c)	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	10,46,16,204/- equity shares of Rs. 1/- each amounting to Rs. 10,46,16,204/-
d)	Whether bonus is out of free reserves created out of profits or share premium account	Share premium account of the Company available as on March 31, 2026
e)	Bonus ratio	1:1 i.e. 1 (One) equity bonus share of Rs. 1/- each for every 1 (One) existing equity share of Rs. 1/- each held as on record date to be determined by Board.
f)	Details of share capital - pre and post bonus issue	Pre-bonus paid up share capital Rs. 10,46,16,204/- divided into 10,46,16,204 equity shares of Rs. 1/- each Post- bonus paid up share capital Rs. 20,92,32,408/- divided into 20,92,32,408 equity shares of Rs. 1/- each
g)	Free reserves and/ or share premium required for implementing the bonus issue	Share premium account amounting to Rs. 10,46,16,204.
h)	Free reserves and/ or share premium available for capitalization and the date as on which such balance is available	Share premium: Rs. 81,97,08,024/- as on March 31, 2026.
i)	Whether the aforesaid figures are audited	Yes
j)	Estimated date by which such bonus shares would be credited/dispatched	Within 2 months from the date of Board Meeting approving the Bonus i.e. by November 22, 2026